

PATENT

Docket No.: 38586-324005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Parhami, Farhad
Appl. No. : 10/524,945
I.A. Filed : August 28, 2003
Title : Agents and Methods
for
Enhancing Bone
Formation


Confirmation No.: 3129

Certificate of Mailing

I hereby certify that this correspondence (along with any documents referred to as attached or enclosed) is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Sequences, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 24, 2005.

Grp./A.U. : Not Yet Assigned
Examiner : Not Yet Assigned
Customer No. : 1923

Signature


John G. Bisbikis, Reg. No. 37,095

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO COMPLY


Dear Sir:

Applicant hereby responds to the Notice To Comply With Requirements for Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures dated August 23, 2005, as required by 37 CFR 1.821 (copy enclosed), and provides a "Sequence Listing" as required by 37 CFR 1.821(c) with the amendment specifically directing its entry into the application and Statement under 37 CFR 1.21 (f) and (g). In addition, a copy of the "Sequence Listing" in computer readable form as required by 37 CFR 1.821 (e) is enclosed herewith. Applicant believes no extensions are required.

If any fees are required in connection with this response, please charge Account No. 13-0206. A duplicate of this transmittal is attached.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP


John Bisbikis, Registration No. 37,095

McDERMOTT WILL & EMERY LLP
227 West Monroe Street
Chicago, Illinois 60606-5096
Telephone 312.372.2000
Facsimile: 312.984.7700
Date: October 24, 2005

**Please recognize our Customer No. 1923
as our correspondence address.**



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/524,945	Farhad Parhami	38586-324005

1923
 MCDERMOTT, WILL & EMERY LLP
 227 WEST MONROE STREET
 CHICAGO, IL 60606-5096

RECEIVED
 AUG 30 2005

MW&E

DOCKETED

10/23/2005

INTERNATIONAL APPLICATION NO.	
PCT/US03/27105	
I.A. FILING DATE	PRIORITY DATE
08/28/2003	08/29/2002

CONFIRMATION NO. 3129
 371 FORMALITIES LETTER
 OC000000016837466
 OC000000016837466

Date Mailed: 08/23/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

JOHN L. ANDERSON

Telephone: (703) 308-9140 EXT 211

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/524,945	PCT/US03/27105	38586-324005

FORM PCT/DO/EO/922 (371 Formalities Notice)